6
|
Conti HR, Bruno VM, Childs EE, Daugherty S, Hunter JP, Mengesha BG, Saevig DL, Hendricks MR, Coleman BM, Brane L, Solis N, Cruz JA, Verma AH, Garg AV, Hise AG, Richardson JP, Naglik JR, Filler SG, Kolls JK, Sinha S, Gaffen SL. IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical for Protection against Oropharyngeal Candidiasis. Cell Host Microbe 2016; 20:606-617. [PMID: 27923704 DOI: 10.1016/j.chom.2016.10.001] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2016] [Revised: 08/16/2016] [Accepted: 09/21/2016] [Indexed: 12/19/2022]
Abstract
Signaling through the IL-17 receptor (IL-17R) is required to prevent oropharyngeal candidiasis (OPC) in mice and humans. However, the IL-17-responsive cell type(s) that mediate protection are unknown. Using radiation chimeras, we were able to rule out a requirement for IL-17RA in the hematopoietic compartment. We saw remarkable concordance of IL-17-controlled gene expression in C. albicans-infected human oral epithelial cells (OECs) and in tongue tissue from mice with OPC. To interrogate the role of the IL-17R in OECs, we generated mice with conditional deletion of IL-17RA in superficial oral and esophageal epithelial cells (Il17raΔK13). Following oral Candida infection, Il17raΔK13 mice exhibited fungal loads and weight loss indistinguishable from Il17ra-/- mice. Susceptibility in Il17raΔK13 mice correlated with expression of the antimicrobial peptide β-defensin 3 (BD3, Defb3). Consistently, Defb3-/- mice were susceptible to OPC. Thus, OECs dominantly control IL-17R-dependent responses to OPC through regulation of BD3 expression.
Collapse
Affiliation(s)
- Heather R Conti
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Biological Sciences, University of Toledo, Toledo, OH 43606, USA.
| | - Vincent M Bruno
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Erin E Childs
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Sean Daugherty
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Joseph P Hunter
- Department of Biological Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Bemnet G Mengesha
- Department of Biological Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Danielle L Saevig
- Department of Biological Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Matthew R Hendricks
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Bianca M Coleman
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Lucas Brane
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Norma Solis
- Division of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA 90502, USA
| | - J Agustin Cruz
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Akash H Verma
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Abhishek V Garg
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Amy G Hise
- Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA; Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA
| | - Jonathan P Richardson
- Department of Mucosal and Salivary Biology, King's College London, London SE1 1UL, UK
| | - Julian R Naglik
- Department of Mucosal and Salivary Biology, King's College London, London SE1 1UL, UK
| | - Scott G Filler
- Division of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA 90502, USA
| | - Jay K Kolls
- Richard King Mellon Foundation for Pediatric Research, Children's Hospital of UPMC, Pittsburgh, PA 15224, USA
| | - Satrajit Sinha
- Department of Biochemistry, University at Buffalo, State University of New York, Buffalo, NY 14203, USA
| | - Sarah L Gaffen
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Mucosal and Salivary Biology, King's College London, London SE1 1UL, UK.
| |
Collapse
|
11
|
Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, Mills G, Argiris A, Grandis JR. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 2009; 27:1235-42. [PMID: 19204206 PMCID: PMC2667824 DOI: 10.1200/jco.2008.17.8251] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE Squamous cell carcinoma of the head and neck (SCCHN) is characterized by upregulation of the epidermal growth factor receptor (EGFR). We developed a novel strategy to target EGFR by using a therapeutic gene that consisted of an EGFR antisense (AS) gene sequence under U6 promoter control. A phase I clinical trial was conducted to evaluate the safety and biologic effects of EGFR AS. PATIENTS AND METHODS Patients with advanced SCCHN who were refractory to standard therapies and who had at least one assessable and accessible lesion were enrolled. The EGFR AS dose was escalated in successive cohorts (six dose levels; 60 to 1,920 microg/injection). Patients received four weekly intratumoral EGFR AS injections. Tumor biopsies were performed before and after completion of therapy. Treatment response was assessed by tumor volume measurements (positron emission tomography/computed tomography), and levels of target proteins were assessed by immunohistochemistry. RESULTS Seventeen assessable patients were treated. No grades 3 to 4 or dose-limiting toxicities were noted, and a maximum-tolerated dose was not reached. Five patients (29%) achieved a clinical response, which included two complete responses (CRs) and three partial responses (PRs); two additional patients had stable disease (SD) as the best response. Patients with disease control (CR + PR + SD) had tumors with higher EGFR and lower STAT3 expression at baseline compared with patients who had progressive disease (P = .0312 and P = .095, respectively). CONCLUSION Intratumoral EGFR AS was safe and resulted in antitumor activity in patients with advanced SCCHN. Baseline levels of high EGFR and low STAT3 may be associated with antitumor effects.
Collapse
Affiliation(s)
- Stephen Y. Lai
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Priya Koppikar
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Sufi M. Thomas
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Erin E. Childs
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Ann Marie Egloff
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Raja R. Seethala
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Barton F. Branstetter
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - William E. Gooding
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Ashok Muthukrishnan
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - James M. Mountz
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Vivian W.Y. Lui
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Dong M. Shin
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Sanjiv S. Agarwala
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Rita Johnson
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Larry A. Couture
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Eugene N. Myers
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Jonas T. Johnson
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Gordon Mills
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Athanassios Argiris
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA
| | - Jennifer R. Grandis
- From the Departments of Otolaryngology, Pharmacology, Pathology, Radiology, and Medicine, University of Pittsburgh Medical Center; and Biostatistics Facilities, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Departments of Head and Neck Surgery and Molecular Therapeutics, University of Texas, The M. D. Anderson Cancer Center, Houston, TX; State Key Laboratory of Oncology in Southern China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta, GA; and National Gene Vector Laboratory, Center for Biomedicine and Genetics, City of Hope National Medical Center, Duarte, CA.,Corresponding author: Jennifer R. Grandis, MD, Eye and Ear Institute, 200 Lothrop St, Suite 500, Pittsburgh, PA 15213; e-mail:
| |
Collapse
|